Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Advantage Therapeutics is spinning off some of its age-related disease R&D into a new company called Klothea Bio. | Klothea ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

To recruit volunteers more quickly for clinical trials, a team of National Institutes of Health (NIH) researchers has turned ...

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) ...

The annual Fierce 50 Gala is set to shine a spotlight on the life sciences industry's most transformative leaders, ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...